We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Chinese leading biopharmaceutical company, 3SBio Inc., announced today that Selecta Biosciences, Inc., the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of ...